fig3

Figure 3. Non-invasive observation of bone metastasis of PC-3/MRS-BLI. A: Schematic demonstrating the administration of ZA or substrates for MRS-BLI in a murine bone metastasis model with PC-3/MRS-BLI; B: Multiplexed bioluminescent imaging of bone metastasis of PC-3/MRS-BLI treated with or without ZA; C: Relative metastasis mass of PC-3/MRS-BLI bone metastasis monitored with CMV-Cluc-GPI. n = 7 (Control), n = 5 (ZA), *P < 0.05; D: Relative NF-κB activity (κB-FlucP/CMV-Cluc-GPI) of PC-3/MRS-BLI bone metastasis. The inset graph highlights NF-κB activity on days 1 through day 12. n = 7 (Control), n = 5 (ZA), *P < 0.05. Red lines indicate the statistical significance of day 1 over day 4 and day 7 in the control group; E: Relative HIF activity (HRE-RlucP/CMV-Cluc-GPI) of PC-3/MRS-BLI bone metastasis. The inset graph highlights HIF activity on day 1 through day 12. n = 7 (Control), n = 5 (ZA), *P < 0.05. Red lines indicate the statistical significance between day 1 (control group) and day 7. ZA: Zoledronic acid; MRS-BLI: multiplexed reporter system for bioluminescent imaging; Cluc: Cypridina luciferase; Fluc: Firefly luciferase; Rluc: Renilla luciferase; GPI: glycosylphosphatidylinositol; NF-κB: nuclear factor-kappa B; HIF: hypoxia-inducible factor